KOLINPHARMA® expands product portfolio with DOLATROX® hcc, DOLTENDIX® and XINPROX®
New product launches in 2021
KOLINPHARMA® expands its orthopedic line with the launch of its first medical device DOLATROX® hcc based on hyaluronic acid, chondroitin sulfate and cyclodextrine and new nutraceutical product DOLTENDIX® sachets, based on bioactive peptides from collagen, astaxanthin, trans-resveratrol and vitamin C, formulated for the well-being od the tendons. Also KOLINPHARMA® expands its uro-gynaecological line with launch of XINPROX® based on Graminex® G63®, quercetin, alpha-lipoic acid, L-tryptophan, formulated for the well-being of the prostate.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance